Latest Breaking News On - George lasezkay - Page 6 : comparemela.com

Clearside Biomedical (CLSD) Announces Acceptance of Arctic Vision s NDA for Arcatus in Australia

Clearside Biomedical (CLSD) Announces Acceptance of Arctic Vision s NDA for Arcatus in Australia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaNew zealandGeorge lasezkayJenny kobin remy bernardaClearside biomedical incExchange commissionTherapeutic goods administrationClearside biomedicalArctic visionUveitic macularGreater chinaChief executive officerMacular edemaDrug administrationSafety information

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

- XIPERE® is referred to as Arcatus by Arctic Vision – ALPHARETTA, Ga., July 10, 2023 Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of.

United statesSouth koreaNew zealandJenny kobinGeorge lasezkayRemy bernardaTherapeutic goods administrationClearside biomedical incGlobenewswire incDrug administrationExchange commissionArctic visionGoods administrationUveitic macularChief executive officerMacular edema

Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

- U.S. Clinical Sites Screening Treatment-Experienced Participants with Wet AMD - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., June 01, 2023 Clearside Biomedical,. | June 1, 2023

Jenny kobinRemy bernardaGeorge lasezkayExchange commissionRetina internationalGlobenewswire incClearside biomedical incResults expectedChief executiveActivity assessmentsAge related macular degenerationSuprachoroidal spaceInjection platformSocio economic impactPrivate securities litigation reform actAnnual report

Clearside Biomedical, Inc (NASDAQ:CLSD) Q1 2023 Earnings Call Transcript

Operator: Good day and thank you for standing by. Welcome to the Clearside Biomedical First Quarter 2023 Financial Results and Corporate Update Call.

Peter changJenny kobinBausch lombTom chulaJonathan wollebenArshad khananiCharlie deignanSerge belangerCharles deignanYi chenDennis marcusGeorge lasezkaySuprachoroidal microinjectorAsia pacificLejla vajzovicAnnabel samimy

Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update

11.05.2023 - - Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 - - Positive Safety Data, Duration and Biologic Effect of CLS-AX Over 6 Months in OASIS Phase 1/2a Extension Study Highlighted in Presentations at Recent Medical .

Thomasa ciullaRemy bernardaJenny kobinArshadm khananiGeorge lasezkayLejla vajzovicDevelopment rd expensesAssociation for researchMacula society annual meetingExchange commissionClearside biomedical incChief executiveExtension studyNew orleansScientific advisory boardDegeneration virtual